Investing.com - BioLineRx reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.2985 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.15 on revenue of $0.00.
BioLineRx shares are up 16.67% from the beginning of the year, still down 53.63% from its 52 week high of $6.34 set on May 4. They are outperforming the Nasdaq which is up 6.46% from the start of the year.
BioLineRx shares lost 0.34% in intra-day trade following the report.
BioLineRx follows other major sector earnings this month
BioLineRx's report follows an earnings beat by Tencent ADR on May 20, who reported EPS of $0.7642 on revenue of $21.03B, compared to forecasts EPS of $0.536 on revenue of $20.58B.
Industrial Commercial Bank of China had beat expectations on April 29 with first quarter EPS of $0.7417 on revenue of $33.09B, compared to forecast for EPS of $0.6343 on revenue of $34.72B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar